MinervaX
Budget
€10 — €0
EP Access
0
accredited persons
Staff
1
0.1 FTE
EU Grants
None
Mission & Goals
MinervaX has advanced its GBS vaccine through clinical trials in 700 healthy adult women, pregnant women, and older adults with very encouraging results and is the leading vaccine candidate currently in development. The programme has been supported by FP7 and EDCTP. MinervaX is currently preparing for Phase 3 clinical studies.
EU Legislative Interests
Mr Per Fischer, representative of MinervaX, would like to introduce the company to EC members and explore how our capabilities within our industry could be leveraged to achieve the goals within the European Commission. MinervaX will be visiting Brussels to attend meetings with various EU Institutions and agencies to discuss feasibility of gaining support relating to the vaccine against Group B Streptococcus (GBS) that is currently undergoing clinical trials. However, our offerings are broad and deep, and we are also keen to gain insight from the EC members as to their perspectives on how MinervaX could bring value to ongoing and future EC needs in the Health Industry across a more comprehensive landscape.
Interests Represented
Promotes their own interests or the collective interests of their members
Organisation Members
Dansk Biotek (www.danskbiotek.dk)
Connected Legislation
Commissioner Meetings
No recorded meetings with EU commissioners.